A detailed history of Vanguard Group Inc transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Vanguard Group Inc holds 1,521,543 shares of PDSB stock, worth $2.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,521,543
Previous 1,408,839 8.0%
Holding current value
$2.5 Million
Previous $4.13 Million 40.83%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.93 - $4.23 $330,222 - $476,737
112,704 Added 8.0%
1,521,543 $5.81 Million
Q2 2024

Aug 13, 2024

SELL
$2.55 - $4.02 $456,365 - $719,447
-178,967 Reduced 11.27%
1,408,839 $4.13 Million
Q1 2024

May 10, 2024

BUY
$3.85 - $6.59 $316,219 - $541,269
82,135 Added 5.46%
1,587,806 $6.29 Million
Q4 2023

Feb 14, 2024

SELL
$3.95 - $6.58 $7,979 - $13,291
-2,020 Reduced 0.13%
1,505,671 $7.48 Million
Q3 2023

Nov 14, 2023

SELL
$4.8 - $6.4 $563,788 - $751,718
-117,456 Reduced 7.23%
1,507,691 $7.61 Million
Q2 2023

Aug 14, 2023

BUY
$5.03 - $9.9 $1.64 Million - $3.23 Million
326,672 Added 25.16%
1,625,147 $8.17 Million
Q1 2023

May 15, 2023

BUY
$5.68 - $11.99 $777,876 - $1.64 Million
136,950 Added 11.79%
1,298,475 $7.99 Million
Q4 2022

Feb 10, 2023

BUY
$3.28 - $13.2 $44,106 - $177,500
13,447 Added 1.17%
1,161,525 $15.3 Million
Q3 2022

Nov 14, 2022

BUY
$2.97 - $5.79 $160,953 - $313,777
54,193 Added 4.95%
1,148,078 $3.41 Million
Q1 2022

May 13, 2022

BUY
$4.78 - $8.43 $377,739 - $666,180
79,025 Added 7.79%
1,093,885 $6.77 Million
Q4 2021

Feb 14, 2022

BUY
$7.76 - $14.35 $288,346 - $533,217
37,158 Added 3.8%
1,014,860 $8.22 Million
Q3 2021

Nov 12, 2021

BUY
$9.33 - $17.08 $132,486 - $242,535
14,200 Added 1.47%
977,702 $14.6 Million
Q2 2021

Aug 13, 2021

BUY
$4.35 - $12.86 $4.19 Million - $12.4 Million
963,502 New
963,502 $12.1 Million

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $46.7M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.